Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECTIONLTE: Long-Term Extension Study of Filgotinib in Ulcerative Colitis
NCT02914535Phase 3Completed
- Sponsor
- Alfasigma
- Start
- Feb 2017
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 39
01
Overview
A Phase 3 trial of filgotinib in ulcerative colitis (UC), sponsored by Alfasigma. Started Feb 2017; status: completed.
02
Drugs
filgotinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02914535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914535.